Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch
- New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders
- Builds on the €50m secured in 2025 and supports Xeltis’ next phase of clinical, regulatory and commercial execution
- Additional €20.5m provides the runway to finalize the ongoing US pivotal trial of aXess™, prepare for FDA submission and US Go-To- Market, fund the European commercial rollout of aXess™, upscale manufacturing capabilities, and advance its XABG and XPAD programs in the clinic
- Follows recent announcement of successful treatment of the first commercial patient in Germany
EINDHOVEN, The Netherlands – 28 July, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announced that it had raised an additional €20.5m of new funding from new and existing shareholders. Participating investors included the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders, alongside Horizon 3 Healthcare, a new investor who led the round.
